0 CHECKOUT

Renal Cancer Drug Pipeline Update

  • ID: 1196693
  • February 2016
  • Region: Global
  • Bioseeker
1 of 2

The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets.

There are today 236 companies plus partners developing 254 drugs targeting renal cancer in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 96 drugs. Renal Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 227 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 221 out of the 223 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized READ MORE >

Note: Product cover images may vary from those shown
2 of 2



Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
3 of 2
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amgen Inc.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Bristol-Myers Squibb
  • Bayer AG
  • Pfizer Inc.